Ready To Use Products

One Platform, Endless Possibilities

Unleash the potential of our Ready to Use Products, crafted to transform research and healthcare innovation. From vaccine development to personalized cancer care, each UISS platform offers precision, speed, and reliability to address complex biological challenges.

Accelerate breakthroughs, minimize risks, and explore new horizons with solutions designed to empower your work.

Discover our Ready to Use Solutions

The Universal Immune System Simulator – Mammary Carcinoma (UISS-MC) is an advanced agent-based model designed to simulate the effects of tumor-preventive cell vaccines in HER-2/neu transgenic mice predisposed to mammary carcinoma.

By integrating a powerful genetic algorithm, UISS-MC optimizes vaccination schedules, proposing highly effective cancer-preventive protocols that rival those developed by human experts.

In collaboration with the Università degli Studi di Catania (UNICT) and utilizing anonymized data from the Istituto Europeo di Oncologia, UISS-MC is being expanded for clinical applications. This extension will validate its predictive accuracy and adaptability to patient-specific models.

Through retrospective experimental data, UISS-MC is poised to revolutionize the prediction and design of immunotherapy strategies for human mammary carcinoma, setting a new benchmark in personalized cancer care.

UISS-Thyroid is a cutting-edge computational platform addressing resistance to therapies in thyroid cancer, particularly in cases involving the BRAF V600E mutation. Despite the clinical use of vemurafenib, its limited efficacy in poorly differentiated and anaplastic thyroid cancers highlights the need for innovative solutions.

 

Through in silico modeling, UISS-Thyroid identified MAP3K8 as a critical target in cancer stem cell-mediated resistance. This prediction was confirmed via in vitro experiments, where MAP3K8 inhibition restored vemurafenib’s effectiveness, promoting apoptosis in resistant cells.

 

UISS-Thyroid empowers researchers to develop precision strategies for overcoming therapeutic resistance in thyroid cancer.

Effective melanoma treatment requires activating tumor-specific cytotoxic T lymphocytes (CTLs) and ensuring their efficient migration and targeting of tumor cells. UISS Melanoma, an advanced in silico platform, replicates these complex dynamics with remarkable precision.

 

Validated through in vivo experiments against B16-melanoma in mice, UISS Melanoma demonstrated outstanding accuracy in predicting tumor progression and immunotherapy outcomes. It revealed critical insights, such as the pivotal role of CD137 expression on tumor vessels in therapy success.

 

UISS Melanoma offers researchers a powerful tool to anticipate treatment outcomes, optimize preclinical strategies, and innovate therapies with unmatched speed and reliability.

UISS MS is an advanced computational tool designed to simulate the immune system and its interaction with multiple sclerosis (MS) pathogenesis. By modeling relapsing MS dynamics, it predicts disease progression and response to treatments, supporting personalized therapeutic strategies.

 

Using real patient data—including age, sex, MRI lesion load, and therapy history—UISS MS has accurately replicated clinical outcomes and anticipated relapse timings in specific cases. This multi-scale, agent-based platform empowers neurologists with a predictive framework to optimize treatment decisions, monitor therapeutic efficacy, and advance personalized care for MS patients.

The Universal Immune System Simulator (UISS) for COVID-19 is a groundbreaking in silico platform designed to simulate and predict immune system responses against SARS-CoV-2. Leveraging advanced computational modeling, UISS provides unparalleled insights into virus dynamics, immune interactions, and therapeutic outcomes.

 

This platform has been rigorously tested and shown to align closely with real-world data, making it an invaluable tool for accelerating vaccine development and evaluating therapeutic strategies. By minimizing risks, predicting failures, and reducing time-to-market, UISS is reshaping how we combat pandemics, offering precision and speed in the fight against COVID-19.

Influenza poses significant risks, especially to vulnerable populations like the elderly and immunocompromised. While modern subunit vaccines are safer, they often require adjuvants to strengthen immune responses. However, the limited availability of effective, safe adjuvants hampers progress.

 

UISS Flu is an advanced in silico platform that simulates immune responses to influenza A, streamlining vaccine development. It identifies optimal adjuvants, such as citrus-derived Beta Sitosterol, which has shown promising efficacy in silico and been validated in vivo.

 

UISS Flu empowers researchers and developers to accelerate innovation, enhance vaccine performance, and address influenza challenges with precision and confidence.

UISS Sense is a cutting-edge in silico platform designed to simulate human immune responses to skin sensitizers, addressing the critical need for accurate allergenicity prediction. Leveraging the Universal Immune System Simulator, it offers a mechanistic approach to evaluate the immunotoxicity of chemicals, enhancing current alternatives to animal testing.

 

This innovative tool predicts allergic contact dermatitis with precision, bridging gaps in hazard identification and potency evaluation. UISS Sense empowers researchers and regulators with a reliable, ethical solution for assessing skin sensitization, advancing safety standards in chemical product development.

UISS-Tox is an advanced computational platform designed to assess the immunotoxic effects of chemicals like PFAS, known for their impact on immune function and health. By simulating the human immune system, UISS-Tox predicts adverse outcomes such as weakened vaccine responses and increased susceptibility to infections or cancer.

 

This innovative approach enables the repurposing of robust mathematical models for chemical safety assessment, bridging gaps between pharmaceutical and chemical domains. UISS-Tox empowers researchers and regulators with a precise, adaptable tool for identifying immunotoxic hazards, advancing public health and environmental safety.

Want to discover more about our Ready To Use Products?

Contact us!